Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas

NCT02096471 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT02096471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02096471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
August 1, 2018
Enrollment
19 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 1 and growing or symptomatic, inoperable pn